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A B S T R A C T   
Background: Interleukin-1-dependent increases in glycolysis promote allergic airways disease in mice and 
disruption of pyruvate kinase M2 (PKM2) activity is critical herein. Glutathione-S-transferase P (GSTP) has been 
implicated in asthma pathogenesis and regulates the oxidation state of proteins via S-glutathionylation. We 
addressed whether GSTP-dependent S-glutathionylation promotes allergic airways disease by promoting glyco-
lytic reprogramming and whether it involves the disruption of PKM2. 
Methods: We used house dust mite (HDM) or interleukin-1β in C57BL6/NJ WT or mice that lack GSTP. Airway 
basal cells were stimulated with interleukin-1β and the selective GSTP inhibitor, TLK199. GSTP and PKM2 were 
evaluated in sputum samples of asthmatics and healthy controls and incorporated analysis of the U-BIOPRED 
severe asthma cohort database. 
Results: Ablation of Gstp decreased total S-glutathionylation and attenuated HDM-induced allergic airways dis-
ease and interleukin-1β-mediated inflammation. Gstp deletion or inhibition by TLK199 decreased the interleukin- 
1β-stimulated secretion of pro-inflammatory mediators and lactate by epithelial cells. 13C-glucose metabolomics 
showed decreased glycolysis flux at the pyruvate kinase step in response to TLK199. GSTP and PKM2 levels were 
increased in BAL of HDM-exposed mice as well as in sputum of asthmatics compared to controls. Sputum pro-
teomics and transcriptomics revealed strong correlations between GSTP, PKM2, and the glycolysis pathway in 
asthma. 
Conclusions: GSTP contributes to the pathogenesis of allergic airways disease in association with enhanced 
glycolysis and oxidative disruption of PKM2. Our findings also suggest a PKM2-GSTP-glycolysis signature in 
asthma that is associated with severe disease.   
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1. Introduction 
Asthma is a chronic inflammatory disease characterized by airway 
hyperresponsiveness and remodeling [1], processes that are 
energy-demanding. We recently demonstrated that changes in cellular 
metabolism, notably increases in glycolysis occur in allergic airways 
disease in association with interleukin-1 (IL-1)-signaling, and that in-
creases in airway lactate accompany neutrophilic and steroid-resistant 
asthma [2,3]. The last, rate-limiting step of glycolysis is the conver-
sion of phosphoenolpyruvate (PEP) to pyruvate, catalyzed by pyruvate 
kinase M (PKM). The PKM gene consists of two isozymes, PKM2 and 
PKM1. While PKM1 is constitutively active as a glycolysis kinase and 
occurs as a tetramer with high binding affinity for the PEP substrate, 
PKM2 can also exist as dimers or monomers, which have low binding 
affinity for PEP and have non-canonical alternative functions important 
in promoting glycolytic reprogramming and inflammation [4–6]. 
Notably, dimeric PKM2 can translocate into the nucleus and increase the 
expression of pro-inflammatory cytokines in a signal transducer and 
activator of transcription 3 (STAT3)- or hypoxia-inducible factor 1-alpha 
(HIF1α)-dependent manner, thereby enhancing immune cell activation 
[7,8], including the development of Th17 cells [9,10]. We recently 
showed that PKM2 is increased in nasal epithelial cells from subjects 
with asthma as compared to controls [2]. Furthermore, an allosteric 
activator of PKM2 that stabilizes the tetramer and enhances its canonical 
glycolysis activity decreased allergic airways disease in mice along with 
diminished activation of STAT3 [3]. PKM2 can be regulated by a number 
of post-translational modifications including phosphorylation, acetyla-
tion, methylation, and oxidation [11–15]. Oxidation of PKM2 inhibits 
the tetramer form and glycolytic activity [14,16]. It remains unclear 
whether oxidation of PKM2 occurs in asthma and how this oxidative 
process is regulated. 
One type of protein oxidation that is a key regulator of (patho) 
physiological processes is S-glutathionylation (PSSG), the conjugation of 
glutathione (GSH) to cysteine residues in proteins [17]. GSH-adducts 
affect protein structure and function [18]. Glutathione S-transferase P 
(GSTP) is well-known for its role in phase II drug metabolism, but recent 
studies have shown that GSTP is also a catalyst for PSSG [19,20]. 
Importantly, GSTP has already been strongly linked to asthma, as 
polymorphisms in the GSTP gene have been associated with altered 
susceptibility to asthma development [21,22], with some conflicting 
reports [23] and an unclear mechanism of action. It remains uncertain 
whether GSTP contributes to asthma pathophysiology as a catalyst of 
PSSG and whether this is linked to glycolytic reprogramming. In the 
present study, we utilized a house dust mite (HDM) mouse model of 
allergic airway disease or IL-1β-induced acute inflammation in 
conjunction with airway basal cells that globally lack GSTP or a clini-
cally relevant inhibitor of GSTP. We also evaluated sputum samples and 
data from the U-BIOPRED severe asthma cohort. Our studies show that 
GSTP contributes to allergic airways disease in association with 
enhanced glycolysis, and oxidation and disruption of PKM2. We also 
demonstrate correlations between GSTP, PKM2 and glycolysis in sputum 
proteomics and transcriptomics of the U-BIOPRED cohort. These col-
lective observations reveal a putative PKM2-GSTP-glycolysis signature 
in people with severe asthma and shed insights into the various mech-
anism whereby GSTP may promote asthma. 
2. Methods 
2.1. Participant characteristics 
Study participants were enrolled at the asthma clinic in CHU Liège 
(Belgium) (n=40). Healthy subjects were recruited at the hospital and 
University of Liège, Belgium (n=20). The demographic and functional 
characteristics of all subjects used in this study are shown in Table S1. 
The study was approved by the local ethics committee at the University 
of Liège, Belgium (reference 2005/181). Informed consent was obtained 
from all participants. Sputum was induced and processed as previously 
described [2,24,25]. 
The U-BIOPRED cohort consisted of severe non-smoking asthma (SA. 
ns), current/ex-smokers with severe asthma (SAs), mild/moderate non- 
smoking subjects with asthma (MMA) and non-smoking healthy volun-
teers (HV) [26]. Sputum cells and brushings of the lower airways were 
obtained as previously described [26]. Sputum cells were studied by the 
SOMAscan proteomic assay [27,28]. The study was approved by the 
ethics committee for each participating clinical institution, and adhered 
to the standards set by International Conference on Harmonisation and 
Good Clinical Practice, and is registered on ClinicalTrials.gov 
(NCT01976767). All participants gave written and signed informed 
consent. 
2.2. Mouse studies 
Age-matched 8–12 weeks old wild-type (WT) C57BL6/NJ mice (The 
Jackson Laboratory, Bar Harbor, ME) or global Gstp− /− mice (deficient 
in Gstp1 and Gstp2) were bred at the University of Vermont. All animal 
experiments were approved by the Institutional Animal Care and Use 
Committee. Allergic airways disease was induced as described in 
Fig. S1A with intranasal administrations of 10 μg HDM protein [2]. 
In separate experiments, WT and Gstp− /− mice received an intranasal 
administration of 1 μg of IL-1β (R&D Systems). Control groups received 
0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), 
which served as the vehicle for IL-1β. Mice were harvested 6 or 24 h after 
IL-1β administration. 
2.3. Cell experiments 
Primary mouse tracheal epithelial (MTE) cells were isolated from 
C57BL6/NJ WT or Gstp− /− tracheas and cultured as previously 
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described [29]. MTE cells were grown to confluency on 6- or 12-wells 
transwell inserts (Corning, Corning, NY). Cells were starved overnight 
in plain DMEM/F12 phenol red free media supplemented with penicillin 
(50U/mL)-streptomycin (50 μg/mL (P/S) and treated with 1 ng/ml of 
IL-1β (R&D Systems) at indicated timepoints. 
WT MTE cells were also pre-treated with 50 μM of TLK199 (Sigma- 
Aldrich) for 1 h prior to stimulation with 1 ng/ml of IL-1β (R&D Sys-
tems) and re-treated with 50 μM TLK199 8 h post IL-1β treatment. 
TLK199 was dissolved in DMSO (0.05%) and IL-1β in 0.1% BSA in PBS. 
MTE cells were treated at the apical and basolateral side. Basolateral 
medium was collected to assess pro-inflammatory cytokine and lactate 
levels, and cells were harvested for protein and biochemical analyses. 
2.4. Statistical analysis 
Cell experiments were performed at least three times with n=3/ 
group/experiment. Significant differences between groups were evalu-
ated by two-way ANOVA with a Tukey post-hoc test for multiple com-
parison using GraphPad Prism software 8.0 (GraphPad, Inc., La Jolla, 
CA), unless otherwise noted. Values were considered statistically sig-
nificant when p < 0.05. Data are shown as means ± S.E.M. 
Additional details are provided in the online supplement. 
3. Results 
3.1. GSTP expression is predominant in the airway epithelium 
To investigate the role of GSTP in the pathogenesis of allergic air-
ways disease, C57BL6/NJ WT and Gstp− /− mice were sensitized and 
challenged with HDM (Figs. S1A–C). Immunofluorescence staining 
confirmed that GSTP was mainly expressed in the airway epithelium in 
saline- and HDM-exposed lung tissues (Fig. S1C) confirming a prior 
report [30]. In contrast to GSTP protein levels which did not change, 
Gstp mRNA expression decreased in lungs of WT mice subjected to HDM 
compared to saline controls (Fig. S1D). mRNA expression levels of Gstm 
and Gstt were also decreased in HDM-exposed mouse lungs compared to 
saline controls, while Gsto was unaffected. No compensatory changes in 
mRNA expression of other Gst genes occurred in the lungs of WT or 
Gstp− /− mice compared with their respective exposure groups, with the 
exception of a decrease in the mRNA levels of Gstt in HDM-exposed 
Gstp− /− mice compared to respective WT mice (Fig. S1D). 
3.2. Genetic ablation of Gstp attenuates features of HDM-induced allergic 
airways disease 
We next assessed whether ablation of Gstp affected HDM-induced 
airway remodeling or airway hyperresponsiveness (AHR). Gstp abla-
tion diminished HDM-mediated increases in mucus metaplasia, 
MUC5AC levels in the bronchoalveolar lavage fluid (BALF), and sub-
epithelial collagen deposition, and attenuated mRNA expression of 
collagen 1a1 (Col1a1), and alpha smooth muscle actin (Acta2) compared 
to WT counterparts, with trends towards decreases in fibronectin 1 (Fn1) 
mRNA (Fig. 1A–D). Moreover, HDM-mediated increases in AHR were 
attenuated in Gstp− /− mice, notably in the tissue resistance and ela-
stance parameters (Fig. 1E). WT and Gstp− /− mice showed similar in-
creases in BAL cell counts in response to HDM compared to the saline 
controls (Fig. 1F), reflected mainly by increases in eosinophils (Fig. 1G). 
Together, these findings show that GSTP promotes mucus metaplasia, 
subepithelial collagen, and AHR, without eliciting a major impact on 
airway inflammatory cells in response to HDM. 
3.3. Ablation of Gstp attenuates HDM-mediated lactate secretion and 
promotes resistance to IL-1β-induced glycolysis and neutrophilic 
inflammation 
Based on our prior findings that enhanced glycolysis promotes HDM- 
induced AHR and remodeling [2,3], we next assessed if GSTP absence 
also dampened parameters of glycolytic reprogramming. Ablation of 
Gstp attenuated the HDM-mediated increases in lactate in BALF 
(Fig. 2A). No increases in lactate were observed in lung tissue (Fig. 2B). 
In agreement with previous results [2], HDM led to increased expression 
of a number of proteins involved in glycolysis including PKM2, hexo-
kinase 2 (HK2), lactate dehydrogenase A (LDHA), inhibitory kappa B 
kinase epsilon (IKKε), and TANK-binding Kinase 1 (TBK1) in lung tissue 
(Fig. 2C). However, no differences in expression of these proteins were 
found between HDM-exposed WT and Gstp− /− mice in lung lysates 
(Fig. 2C). IL-1β is a major driver of glycolysis in lungs of mice with 
HDM-induced allergic airways disease [2]. Surprisingly, IL-1β levels 
slightly increased in Gstp− /− mice exposed to HDM compared to WT 
mice, while those of CCL20 and IL-33 did not differ (Fig. 2D). 
The decreases in airway lactate following ablation of Gstp may occur 
independently or downstream of IL-1 signaling. To further address this, 
we directly administered IL-1β intranasally to WT or Gstp− /- mice 
(Fig. 3A). GSTP expression in lung tissue was marginally affected by IL- 
1β (Fig. 3B). Although the IL-1β-mediated increases in overall BAL cell 
counts were not different, a significant decrease in neutrophil counts 
occurred in Gstp deficient mice compared to WT counterparts adminis-
tered IL-1β (Fig. 3C–D). Moreover, the IL-1β-mediated increases in the 
pro-inflammatory cytokines TSLP, GM-CSF, and CXCL1 in lung tissue 
were attenuated in Gstp− /- mice compared to WT mice, while increases 
in CCL20 were not affected (Fig. 3E). Lastly, ablation of Gstp also 
abrogated the IL-1β-mediated increases in lactate in the BALF (Fig. 3F). 
Collectively, these results demonstrate that GSTP is a critical mediator 
that promotes IL-1β-induced pro-inflammatory signals and lactate 
secretion in lung tissue. 
3.4. Ablation or TLK199-mediated inhibition of Gstp attenuates IL-1β- 
induced lactate and pro-inflammatory mediators in airway epithelial cells 
As GSTP is highly expressed in airway epithelia, the impact of its 
ablation may have been dampened in the analysis of whole lung tissues. 
We therefore next examined whether GSTP also promotes IL-1 
(β)-induced glycolysis and proinflammatory mediator release from 
airway epithelial cells. MTE cells isolated from WT mice exposed to 1 
ng/mL IL-1β showed increased lactate levels and pro-inflammatory 
cytokine secretion in a time-dependent manner (Figs. S2A–B). Gstp 
deficiency attenuated the IL-1β-induced lactate secretion, as well as the 
release of TSLP and GM-CSF, while CCL20 and CXCL1 were unaffected 
(Fig. 4A–B). We next sought to address whether pharmacological inhi-
bition of GSTP elicited similar responses. TLK199 is the most specific 
GSTP inhibitor to date, with a binding affinity greater than GSH itself 
and is selectively for GSTP over 50-fold greater than the GSTM and 
GSTA classes (inhibition constant [Ki] = 0.4 μM) [31]. Administration of 
TLK199, prior to IL-1β exposure also decreased IL-1β-induced lactate 
secretion and markedly decreased TSLP, GM-CSF and CXCL1 without 
affecting CCL20 (Fig. 4C–D). Pre-treatment of MTE cells with TLK199 
did not affect survival, demonstrating that the results described were not 
due to a loss of cell viability (not shown). To more closely examine the 
effect of GSTP on the glycolysis pathway, MTE cells were cultured in the 
presence of 13C-glucose and treated with TLK199 in combination with 
IL-1β. IL-1β led to increases in most intracellular metabolites in the 
glycolysis pathway, while no clear changes were observed in TCA cycle 
intermediates (Fig. 4E, Fig. S2C). In IL-1β-exposed cells that were also 
treated with TLK199, glycolytic intermediates including 13C-PEP were 
increased similarly to the vehicle IL-1β group. However, a shift in the 
glycolysis cascade was observed in IL-1β-exposed cells in the last step of 
the pathway, the conversion from PEP to pyruvate, which is catalyzed by 
PKM. Interestingly, in cells exposed to TLK199 both total pyruvate and 
lactate decreased. In response to IL-1β, intracellular pyruvate and lactate 
were decreased compared to controls, consistent with increases in 
expression of Ldha in IL-1β-stimulated cells [2] which mediates the 
conversion of pyruvate to lactate which is then secreted (Fig. 4C). These 
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Fig. 1. Genetic ablation of Gstp attenuates mucus metaplasia, subepithelial collagen, markers of airway remodeling, and airway hyperresponsiveness in 
mice with HDM-induced allergic airway disease. A, Assessment and quantification of mucus metaplasia by PAS staining intensity (original magnification, ×200). 
B, MUC5AC protein content in BAL fluid. n=5 per group. C, Assessment and quantification of collagen deposition by Masson’s trichrome staining (original 
magnification, ×200). D, mRNA expression of Col1a1, Fn1, and Acta2 (α-smooth muscle actin) normalized to Ppia. E, Assessment of airway responsiveness to inhaled 
methacholine using a Flexivent small animal ventilator. F, Total, and G, Differential cell counts in BAL fluid. n=8–10 per group unless otherwise noted. * respective 
saline vs HDM group; # WT HDM vs Gstp− /− HDM. */#p < 0.05 analyzed by two-way ANOVA. 
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findings point to a potential disruption of the glycolysis cascade 
following GSTP inhibition at the level of pyruvate kinase. Collectively, 
these data show that GSTP promotes IL-1β-induced glycolysis and 
pro-inflammatory cytokine secretion from epithelial cells. 
3.5. GSTP-linked S-glutathionylation of PKM2 disrupts its tetramer 
configuration and attenuates PKM2’s glycolytic activity 
As stated earlier, GSTP catalyzes the forward PSSG reaction [18]. We 
therefore investigated whether GSTP contributes to increases in PSSG in 
HDM-induced allergic airways disease [32]. As expected, HDM led to 
increases in PSSG in WT mice, while PSSG was attenuated in 
HDM-exposed lungs from Gstp− /− mice compared to the respective WT 
group (Fig. 5A). Based upon our results suggesting that TLK199 in-
terferes in the glycolysis cascade at the pyruvate kinase step (Fig. 4E), 
our prior findings that the small molecule allosteric activator of PKM2, 
TEPP46, dampens allergic airway inflammation in mice [3], and pre-
vious observations that PKM2 contains reactive cysteines that can be 
oxidized to disrupt function [14,16], we next addressed whether PKM2 
could be S-glutathionylated by GSTP. Immunoprecipitation of S-gluta-
thionylated proteins followed by western blotting of PKM2 showed in-
creases in S-glutathionylation of PKM2 (PKM2-SSG) in HDM-exposed 
mouse lungs (Fig. 5B). Direct exposure of recombinant PKM2 to oxidized 
GSH (GSSG), a condition that induces PSSG, was sufficient to cause a 
decrease of PKM2 glycolytic activity (Fig. 5C). We next addressed 
whether GSTP can directly interact with PKM2, via protein-protein 
docking with crystal structures of PKM2 and GSTP, and confirmation 
of complex stability by conventional molecular dynamics (MD) simu-
lations (Fig. 5D, Fig. S3). Docking studies and binding affinity calcula-
tions predicted that both dimeric and tetrameric PKM2 can interact with 
GSTP, with a more likely interaction between GSTP with PKM2 tetra-
mers as compared to PKM2 dimers due to the larger interface and more 
contacts (Table S2, Fig. S3). Co-immunoprecipitation of GSTP and PKM2 
confirmed an increased interaction between GSTP and PKM2 in IL-1β 
exposed mouse lungs (6 h), as well as in IL-1β-treated lung epithelial 
cells compared to the control groups (Fig. 5E–F). Interestingly, the GSTP 
inhibitor TLK199 tended to decrease the interaction between GSTP and 
PKM2 (Fig. 5F). Altogether, these data suggest a model wherein GSTP 
binds to PKM2 resulting in its S-glutathionylation, thereby disrupting 
the tetramer and decreasing its canonical glycolysis activity. 
3.6. Gstp ablation or inhibition reduces phosphorylation of STAT3 
The glycolysis inactive monomer/dimer form of PKM2 has alterna-
tive functions as a protein kinase, transcriptional activator, and also can 
exert functions following its secretion [3,7,11,33]. PKM2 promotes 
inflammation in part via phosphorylation of STAT3 (p-STAT3) [7,8]. We 
recently showed that STAT3 contributes to IL-1β-induced lung inflam-
mation in association with disruption of PKM2’s canonical glycolysis 
activity, and that the allosteric activator of PKM2, TEPP46, attenuated 
p-STAT3 [3]. We therefore addressed whether GSTP status also affects 
p-STAT3. HDM- or IL-1β-mediated increases in p-STAT3 in lung tissue 
[3] or MTE cells were abolished following ablation of Gstp (Figs. S4A–B). 
Inhibition of GSTP with TLK199 also decreased the IL-1β-induced 
p-STAT3 in MTE cells (Fig. S4C). Collectively, these results indicate that 
STAT3 is one of the downstream targets that promotes IL-1β-induced 
airway inflammation following the GSTP-mediated S-glutathionylation. 
3.7. GSTP and PKM2 expression are increased in sputum of asthmatics 
with high levels of IL-1β and lactate 
We recently reported that sputum lactate and IL-1β levels were 
elevated in patients with neutrophilic asthma in association with severe 
disease and diminished FEV1 [2]. IL-1 has been linked to neutrophilic 
inflammation, airflow obstruction and steroid resistance in subjects with 
severe asthma [34,35]. Given the present demonstration that GSTP and 
PKM2 govern pro-inflammatory responses to IL-1β, and that GSTP and 
PKM2 can be localized extracellularly [33,36], we next examined 
whether GSTP and PKM2 could be detected in mouse BALF or induced 
sputum samples of healthy controls or people with asthma and could 
serve as potential biomarkers of disease. Interestingly, GSTP and PKM2 
were both increased in BALF of mice exposed to HDM (Fig. 6A). In 
Gstp− /− mice, BAL PKM2 was decreased, suggesting that GSTP promoted 
the secretion of PKM2. We next evaluated GSTP and PKM2 in sputum 
samples of controls (n=20) and participants with asthma [2], and 
distinguished asthma subjects into subgroups having low sputum lactate 
Fig. 2. Genetic ablation of Gstp attenuates HDM-mediated lactate secretion. Measurements of lactate levels in A, BAL fluid and B, lung tissue. C, Representative 
Western blot analyses for HK2, PKM2, LDHA, TBK1, IKKε. β-actin is used as the loading control. D, Measurements of IL-1β, CCL20, and IL-33 in lung tissue ho-
mogenates by ELISA. n=9–10 per group. *p < 0.05 analyzed by two-way ANOVA. 
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and low IL-1β (n=20) vs high sputum lactate and high IL-1β (n=20) 
(Fig. 6B–C, Table S1). Despite some variability between participants, 
GSTP levels were highest in the subgroup of asthma subjects having high 
sputum IL-1β and high sputum lactate, while PKM2 trended towards 
being increased in both asthma groups (Fig. 6B and C and Fig. S5). 
Interestingly, the subgroup of asthma subjects having high sputum IL-1β 
and high sputum lactate also displayed more sputum neutrophils 
compared to the asthma subjects with low sputum IL-1β and lactate 
(p=0.001). We next evaluated GSTP and PKM2 in a larger subject cohort 
by evaluating bronchial brush transcriptomics, sputum transcriptomics, 
and sputum proteomics in the U-BIOPRED adult severe asthma cohort 
[26]. In all databases, the KEGG glycolysis pathway was significantly 
correlated with the expression of GSTP and PKM2 (Fig. 6D). Intrigu-
ingly, a significant correlation was also observed between GSTP and 
PKM2 mRNA in bronchial brushings as well as in sputum (Fig. 6D and E). 
4. Discussion 
Enhanced glycolysis is a process that accompanies allergic airway 
disease and promotes airway remodeling in mice [2]. Increases in the 
oxidative environment promote glycolysis and accompany asthma [32, 
37,38]. Here, we demonstrate a close link between glycolysis and 
oxidative changes and illuminate a role for GSTP, a catalyst of S-gluta-
thionylation, in promoting glycolytic reprogramming. Notably, we show 
that GSTP contributes to IL-1-induced glycolysis and pro-inflammatory 
signaling in epithelial cells and that GSTP binds to and disrupts 
PKM2’s canonical glycolysis activity. GSTP levels were increased in the 
sputum of people with severe asthma, and sputum proteomics and 
transcriptomics also revealed strong correlations between GSTP, PKM2, 
and glycolysis. Together with our previous observations showing that 
inactivation of PKM2’s canonical glycolysis function contributes to 
HDM-induced allergic airways disease [3], these findings point to a 
putative PKM2-GSTP-glycolysis signature in asthma associated with 
severe disease. 
An involvement of GSTs in asthma was first suggested by findings 
that polymorphisms in GSTP, GST-mu, and GST-omega showed links to 
asthma susceptibility, and led to numerous studies to date that have 
provided inconclusive evidence about the linkage of these poly-
morphisms with asthma susceptibility and/or severity [21,23,39,40]. 
Previous studies showed that Gstp transcript levels were down-regulated 
in lung tissues from mice challenged with HDM [41], in an ovalbumin 
model of allergic airways disease [42], and in nasal epithelial cells from 
children with asthma [41]. The latter findings are in agreement with 
decreases in Gstp transcripts in lung tissue in response to HDM shown 
herein that occurred in the absence of changes in GSTP protein levels. 
Our results show that GSTP contributes to the pathogenesis of 
HDM-induced allergic airways disease and promotes mucus metaplasia, 
airway remodeling, and AHR. Our results contrast a study using oval-
bumin that demonstrated enhanced AHR, eosinophilia, and goblet cell 
hyperplasia in Gstp− /− mice. The latter findings depended on the genetic 
Fig. 3. Gstp absence attenuates the release of pro-inflammatory cytokines and decreases airway neutrophilia following intranasal administration of IL-1β. 
A, Schematic depicting the intranasal administration of 1 μg of IL-1β for either 6 or 24 h. The total cell count and cell differentials in the BAL fluid reflect 24 h post IL- 
1β treatment, the other results shown are obtained 6 h post IL-1β administration. B, Representative western blots for total GSTP levels. β-actin; loading control. C, 
Total, and D, Differential cell counts in BAL fluid. E, Levels of the pro-inflammatory cytokines TSLP, GM-CSF, CXCL1 and CCL20 in lung tissue homogenates by 
ELISA. F, Measurements of lactate levels in BAL fluid. n=4–8 per group. *p < 0.05 analyzed by two-way ANOVA. 
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background [42] and collectively suggest strain- and 
allergen-dependent effects of Gstp ablation. 
Our results provide new insights into the potential mechanism(s) 
whereby GSTP promotes asthma by the demonstrations that GSTP 
contributes to IL-1β-induced glycolysis and pro-inflammatory signaling 
in epithelial cells, and that GSTP disrupts the canonical glycolysis 
function of PKM2 while increasing its pro-inflammatory function. The 
molecular details whereby GSTP binds and S-glutathionylates PKM2 and 
the cysteine(s) in PKM2 that are oxidized will require further study. 
Oxidation of Cys358 or Cys424 of PKM2 disrupt the tetramer and pro-
mote dimer formation [14,16,43] suggesting that these cysteines also 
may be involved in GSTP-linked oxidation. PKM2 has emerged as a key 
regulator of immune cell activation by acting as a “moonlighting” 
enzyme in the dimer state. While disruption of the PKM2 tetramer slows 
the conversion of PEP to pyruvate, paradoxically, disrupted PKM2 
promotes glycolytic reprogramming by acting as a protein kinase and 
Fig. 4. Ablation or inhibition of Gstp, by TLK199, attenuates IL-1β-induced lactate and pro-inflammatory responses in primary MTE cells. A, Measurements 
of lactate and B, pro-inflammatory cytokines TSLP, GM-CSF, CXCL1, and CCL20 in cell culture supernatants of wild-type and Gstp− /- MTE cells. n=3–9 per group. C, 
Wild-type MTE cells were pre-treated with 50 μM TLK199 for 1 h followed by stimulation of 1 ng/mL IL-1β for 24 h. Lactate levels, and D, levels of pro-inflammatory 
cytokines in cull culture supernatants. n=3–9 per group. E, Metabolomics data of total levels (unlabeled fraction and labelling with 13C glucose) of metabolites in the 
glycolysis pathway. n=5–6 per group. The heavy metabolites are presented with solid color panels and are depicted as M+3 (green/blue), M+5 (purple), and M+6 
(orange). The unlabeled portion of each metabolite is depicted as M and presented with solid white color panels. *p < 0.05 analyzed by two-way ANOVA. (For 
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 5. GSTP-linked S-glutathionylaton of Pyruvate Kinase M2 attenuates its glycolysis activity. A, Total PSSG in lung tissue from saline- and HDM-exposed 
WT and Gstp− /- mice, analyzed by DTNB assay. n=9–10 per group. B, Representative Western blot of PKM2-SSG in saline vs HDM-exposed mouse lungs. C, Pyruvate 
kinase enzymatic activity assay of 10 ng recombinant PKM2 incubated with 50 μM oxidized glutathione (GSSG). D, Complex models and interactions between 
dimeric or tetrameric PKM2 with a GSTP dimer by protein-protein docking. PDB structures used for modeling: 1T5A (PKM2 tetramer) and 1AQW (GSTP dimer). The 
most likely models are illustrated here, and all predicted models are shown in a cartoon in the supplemental information. E, Representative western blots of GSTP- 
PKM2 interaction via co-immunoprecipitation and total PKM2 levels in IL-1β-treated mouse lung tissues. F, Representative Western blot of PKM2-GSTP (IP: PKM2; IB; 
GSTP) and total PKM2 levels in wild type MTE cells pre-treated with 50 μM TLK199 for 1 h followed by stimulation with 1 ng/ml IL-1β for 2 h *p < 0.05 analyzed by 
two-way ANOVA. 
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transcriptional regulator to augment expression of glycolysis genes. 
Nuclear dimeric PKM2 phosphorylates STAT3 [7,8] and increases the 
transcriptional activation of HIF1a target genes to collectively promote 
glycolytic reprogramming, and the latter non-canonical function also 
elicits pro-inflammatory responses. A role of PKM2 in the differentiation 
of Th17 cells has been demonstrated [10] and was shown to involve 
activation of STAT3 [9]. Administration of the small molecule activator, 
TEPP46, which stabilizes the PKM2 tetramer, attenuated HDM- and 
IL-1β-mediated allergic airways disease and pro-inflammatory signaling, 
in association with diminished p-STAT3 [3]. The decrease of 
IL-1-induced pro-inflammatory mediators and STAT3 phosphorylation 
in the absence of Gstp or upon its inhibition described herein are similar 
to the effects of TEPP46. The possibility that TEPP46 protects PKM2 
from inactivation caused by GSTP-mediated S-glutathionylation awaits 
further study. 
Besides PKM2, other targets of GSTP-mediated S-glutathionylation 
also have the potential to contribute to allergic airways disease. For 
example, GSTP increases the proteolytic activity of the protease Der p1 
in HDM [44]. GSTP can also glutathionylate AMPK, SRC and IKK-β, 
leading to decreases of their activity [45–47]. It is worthy of mention 
that IL-1β itself is a target for S-glutathionylation which enhances its 
biological activity [48]. Moreover, GSTP may also regulate protein 
function following binding to client proteins. One well-described bind-
ing partner of GSTP is c-Jun N-terminal kinase (JNK), which promotes 
allergic airways disease [49,50]. Further studies to unravel the proteins 
that GSTP interacts with, the cell types wherein this occurs, along with 
the targets of S-glutathionylation will provide a more complete 
description of the proteins and processes affected by GSTP in settings of 
allergic inflammation [17]. 
Altogether, these data demonstrate that GSTP contributes to HDM- 
induced allergic airways disease in association with enhanced glycol-
ysis. Our findings illuminate that one important target of GSTP- 
controlled S-glutathionylation is PKM2, a major regulator of glycolytic 
reprogramming and inflammation. Lastly, the demonstration that GSTP 
increases IL-1-induced pro-inflammatory signaling, combined with the 
role of IL-1β in neutrophilic severe asthma [2,34,35], suggest that tar-
geting the GSTP/PKM2 axis may offer potential novel treatment stra-
tegies for patients with difficult-to-treat asthma. TLK199 has been used 
clinically with demonstrated therapeutic efficacy in patients with mye-
lodysplastic syndrome [51,52], findings that warrant its clinical rede-
velopment. Furthermore, clinical trials employing a small molecule 
activator of PK are currently ongoing for different clinical indications 
(NCT02476916, NCT04000165, Clinicaltrials.gov), endeavors that 
collectively point to putative strategies to harness PKM2 and GSTP in 
patients with severe asthma in the future. 
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